Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Charite University, Berlin, Germany
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05063058CT.gov Biomarker-driven Therapy for Melanoma | — | Completed | — | — | — |
NCT01303341CT.gov Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma | — | Active Not Recruiting | — | — | — |
NCT01078961CT.gov An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma | — | Completed | — | — | — |
NCT00794235CT.gov Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine | — | Completed | — | — | — |
NCT00623402CT.gov Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma | — | Completed | — | — | — |
NCT00281957CT.gov Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery | — | Completed | — | — | — |
NCT00483301CT.gov A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma | — | Completed | — | — | — |
NCT00673361CT.gov Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma | — | Terminated | — | — | — |
NCT00498836CT.gov Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma | — | Completed | — | — | — |
NCT00418496CT.gov Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma | — | Completed | — | — | — |
Show 8 more trialsShow fewer
NCT00387751CT.gov Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma | — | Completed | — | — | — |
NCT01851408CT.gov Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma | — | Withdrawn | — | — | — |
NCT00349206CT.gov Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma | — | Completed | — | — | — |
NCT00110019CT.gov Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT00119249CT.gov Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery | — | Completed | — | — | — |
NCT00111007CT.gov A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma | — | Completed | — | — | — |
NCT00492297CT.gov A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma | — | Completed | — | — | — |
NCT00110994CT.gov Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sorafenib (this asset) | Charite University, Berlin, Germany | P3 | B · 60 |
| Gm-Csf | Ultimovacs ASA | P4 | BBB |
| Sargramostim | Mayo Clinic | P3 | BBB |
| Cediranib | M.D. Anderson Cancer Center | P3 | BBB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
| Cyclophosphamide | Primmune Therapeutics, Inc. | P4 | BB |
| Temsirolimus | University of Regensburg | P2 | BB |
| Tebentafusp | Immunocore Ltd | P3 | BB |
| Dacarbazine | Suzhou BlueHorse Therapeutics Co., Ltd. | P3 | BB |
+42 more in the Melanoma cohort
Other indications for Sorafenib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P4 | BBB · 79 |
| Portal Vein Thrombosis | — | P4 | BBB · 74 |
| Adult Hepatocellular Carcinoma | — | P3 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sorafenib in Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sorafenib-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →